BioAge Labs (BIOA) Net Equity Issued and Repurchased (2024 - 2026)

BioAge Labs (BIOA) posted Net Equity Issued and Repurchased of $124.3 million for Q1 2026, down 26.87% sequentially from $170.0 million in Q1 2024.

BioAge Labs (BIOA) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends

BioAge Labs has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $124.3 million in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $124.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.3 million (changed N/A YoY) and the FY2024 annual result came in at $170.0 million, changed N/A from the prior year.
Net Equity Issued and Repurchased slipped to $124.3 million in Q1 2026 per BIOA's latest filing, from $170.0 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $170.0 million in Q1 2024 and troughed at $124.3 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	-
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	700,000.00
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	84.80 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	BioAge Labs	427.31 Mn	427.31 Mn	-14.23 Mn	-

Download Data